Organon & Co. filed a current report on October 30, 2026, furnishing supplemental non-GAAP financial metrics for the quarter ended September 30, 2026, in place of its customary quarterly earnings press release and conference call.

Key Highlights

  • Filing date: October 30, 2026, covering the quarter ended September 30, 2026.
  • Merger context: Organon disclosed that it has suspended its customary quarterly earnings press release and earnings conference call in light of its pending merger with Sun Pharmaceutical Industries Limited.
  • Non-GAAP disclosure: Supplemental non-GAAP financial metrics for Q3 2026 were furnished as Exhibit 99.1, intended to be read alongside GAAP financial statements.
  • Regulation FD: The disclosure was made under Item 7.01 (Regulation FD Disclosure) and is characterized as "furnished," not "filed," under Section 18 of the Securities Exchange Act of 1934.
  • Forward-looking statements: The filing states that Exhibit 99.1 contains forward-looking statements and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.
  • Signatory: The report was signed by Matthew Walsh, Chief Financial Officer of Organon & Co.

Organon Maintains Non-GAAP Reporting Practice During Pending Sun Pharma Acquisition

Organon & Co. (NYSE:OGN), a Delaware-incorporated pharmaceutical company headquartered at 30 Hudson Street, Floor 33, Jersey City, NJ, filed a current report on October 30, 2026, under Item 7.01 (Regulation FD Disclosure). According to the filing, Organon is a company with an established practice of publishing supplemental non-GAAP financial metrics alongside its GAAP results each quarter, a practice it has continued even as its ordinary earnings communications have been suspended.

The filing states that, "in light of the Company's pending merger with Sun Pharmaceutical Industries Limited, the Company has suspended its customary practice of issuing a quarterly earnings press release and hosting an earnings conference call." To preserve continuity of financial transparency, the company instead furnished non-GAAP metrics for the quarter ended September 30, 2026, as Exhibit 99.1 to this current report. The filing notes these supplemental measures are provided based on "the belief that this information assists in understanding the Company's financial performance, but not as a substitute for the Company's financial results under GAAP."

The company also disclosed that a quarterly report covering the same period was filed separately with the SEC on October 30, 2026, and that the non-GAAP metrics in this current report should be read in conjunction with the GAAP financial statements contained in that quarterly report. The filing explicitly states the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended."

What Was Disclosed

Organon & Co. furnished supplemental non-GAAP financial metrics for Q3 2026 via a current report dated October 30, 2026, noting its standard earnings press release and conference call have been suspended due to a pending merger with Sun Pharmaceutical Industries Limited.